-

Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced the departure of executive vice president Michael-Bryant Hicks (“Hicks”). He joined Elanco in 2018 as General Counsel and Corporate Secretary to prepare the company for IPO, build the Legal department structure for the stand-alone company, and complete the successful acquisition of Bayer Animal Health.

“I am grateful to Hicks for his contributions to Elanco, providing the legal expertise we needed to successfully transform into a stand-alone animal health company while completing the industry’s biggest acquisition,” said Jeff Simmons, president and CEO at Elanco. “His skill set is unique, and I fully support his aspiration to lead other companies through the same type of dynamic transformation Elanco’s undertaken.”

Hicks will depart Elanco on March 2 and the process to backfill the role is currently underway.

“The last three years at Elanco have been some of the most rewarding in my career, with the opportunity to work alongside talented teammates and make significant contributions in the company’s formative years,” said Michael-Bryant Hicks. “I’m looking forward to taking this experience forward to help others navigate these same types of exciting opportunities.”

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

Contacts

Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com
Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com

Elanco Animal Health Incorporated

NYSE:ELAN

Release Versions

Contacts

Media: Colleen Parr Dekker +1.317.989.7011 colleen_parr_dekker@elanco.com
Investor Relations: Tiffany Kanaga +1.302.897.0668 kanaga_tiffany@elanco.com

More News From Elanco Animal Health Incorporated

Elanco to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8-10, 2024. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts on Tuesday, January 9, 2024 at 3:00 p.m. PST (6:00 PM EST). A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days....

Elanco to Participate in Evercore ISI 6th Annual HealthCONx Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Evercore ISI 6th Annual HealthCONx Conference, November 28-29, 2023. Todd Young, Executive Vice President and CFO, will participate in a fireside chat on Wednesday, November 29 at 8:20 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health Incorpor...

Elanco Animal Health Reports Third Quarter 2023 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2023, provided guidance for the fourth quarter of 2023, and updated guidance for the full year 2023. “Elanco delivered a strong third quarter across both pet health and farm animal, with revenue, adjusted EBITDA, and adjusted EPS growth. Constant currency revenue growth of 5 percent was driven by accelerating contribution from innovation, stabilizing core v...
Back to Newsroom